1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 5, 49, 38, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Oropharyngeal Cancer - Overview
- Oropharyngeal Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Oropharyngeal Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Oropharyngeal Cancer - Companies Involved in Therapeutics Development
- Oropharyngeal Cancer - Drug Profiles
- Oropharyngeal Cancer - Dormant Projects
- Oropharyngeal Cancer - Discontinued Products
- Oropharyngeal Cancer - Product Development Milestones
- Featured News & Press Releases
- Sep 14, 2021: ISA Pharmaceuticals receives Fast Track Designation for lead product ISA101b
- Sep 08, 2021: ISA Pharmaceuticals commences patient treatment in third phase 2 clinical trial with the combination of ISA101b and Libtayo (cemiplimab)
- Jun 17, 2020: ISA Pharmaceuticals strengthens strategic immuno-oncology collaboration with Regeneron
- Oct 14, 2019: ISA Pharmaceuticals receives EUR 20m loan from European Investment Bank
- Sep 30, 2019: Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
- Jan 22, 2019: ISA Pharmaceuticals randomises first patient in OPC drug trial
- Jan 21, 2019: ISA Pharmaceuticals announces start of phase 2 combination trial of ISA101b and Regeneron's Cemiplimab in oropharyngeal cancer
- Dec 20, 2018: Transgene completes safety and tolerability assessment of TG4001 in combination with Avelumab in phase 1b part of trial in HPV-positive cancer patients
- Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
- Apr 26, 2018: ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center
- Mar 26, 2018: Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
- Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
- Sep 11, 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer
- Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage
- Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Oropharyngeal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Oropharyngeal Cancer - Dormant Projects, 2022
- Oropharyngeal Cancer - Dormant Projects, 2022 (Contd..1)
- Oropharyngeal Cancer - Discontinued Products, 2022
- Number of Products under Development for Oropharyngeal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Advaxis Inc
- Agenus Inc
- Akeso Inc
- Anteris Technologies Ltd
- Ascenta Therapeutics Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Aveta Biomics Inc
- Bayer AG
- BioAtla Inc
- Biomimetix JV LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Brooklyn ImmunoTherapeutics Inc
- Compugen Ltd
- Corvus Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- Cue Biopharma Inc
- Dracen Pharmaceuticals Inc
- Eisai Co Ltd
- EpicentRx Inc
- Exelixis Inc
- F-star Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Genentech USA Inc
- Genexine Inc
- Genocea Biosciences Inc
- GeoVax Labs Inc
- Gilead Sciences Inc
- GSK plc
- Hookipa Pharma Inc
- I-Mab
- IMV Inc
- Incyte Corp
- Innovent Biologics Inc
- IO Biotech Inc
- ISA Pharmaceuticals BV
- Jiangsu Hengrui Medicine Co Ltd
- Mabpharm Ltd
- Merck & Co Inc
- Merck KGaA
- Moderna Inc
- NexImmune Inc
- Oncolys BioPharma Inc
- Oncorus Inc
- Ono Pharmaceutical Co Ltd
- PDS Biotechnology Corp
- Pfizer Inc
- Precigen Inc
- PsiOxus Therapeutics Ltd
- Regeneron Pharmaceuticals Inc
- Rubius Therapeutics Inc
- Sanofi
- Scancell Holdings Plc
- Scholar Rock Inc
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shattuck Labs Inc
- Syntrix Pharmaceuticals
- Tessa Therapeutics Ltd
- Theravectys SA
- Transcenta Holding Ltd
- Transgene SA
- Turnstone Biologics Inc
- Vaccinex Inc
- VasGene Therapeutics Inc
